| Ms Lianne Margaret Dehnam, ANP BC | |
|
1235 Whitehorse Mercerville Rd, Suite 316 Bldg. C, Mercerville, NJ 08619-3810 | |
| (609) 581-5586 | |
| (609) 581-5779 |
| Full Name | Ms Lianne Margaret Dehnam |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 1235 Whitehorse Mercerville Rd, Mercerville, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912984014 | NPI | - | NPPES |
| 223709512 | Other | NJ | HORIZON |
| NN088588 | Other | NJ | STATE LICENSE NUMBER |
| 500018409 | Other | NJ | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | NN088588 (New Jersey) | Secondary |
| 363L00000X | Nurse Practitioner | 26NN08858800 (New Jersey) | Primary |
| Entity Name | Advocare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770538696 PECOS PAC ID: 3678562188 Enrollment ID: O20040510001217 |
News Archive
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today released an examination of the federal government's system to produce medications, vaccines, equipment and supplies needed for a health emergency, known as medical countermeasures. The Public Health Emergency Medical Countermeasure Enterprise Review: Transforming the Enterprise to Meet Long Range National Needs reviews the process and makes recommendations for a better approach.
We constantly grow new skin and slough off the old. Until now, scientists have never agreed on exactly how this works, but new research from the University of Sheffield may provide the answer.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
The first two clinical trials for CRISPR-based treatments for inherited blood disorders have been successful.
Research into engineering artificial organs that mimic the functions of human lymph nodes at The University of Alabama in Huntsville has garnered one of its professors a $507,777 National Science Foundation Faculty Early Career Development Program Award.
› Verified 1 days ago
| Entity Name | Stawicki And Patnaik Medical Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730291279 PECOS PAC ID: 7012963184 Enrollment ID: O20050323000047 |
News Archive
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today released an examination of the federal government's system to produce medications, vaccines, equipment and supplies needed for a health emergency, known as medical countermeasures. The Public Health Emergency Medical Countermeasure Enterprise Review: Transforming the Enterprise to Meet Long Range National Needs reviews the process and makes recommendations for a better approach.
We constantly grow new skin and slough off the old. Until now, scientists have never agreed on exactly how this works, but new research from the University of Sheffield may provide the answer.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
The first two clinical trials for CRISPR-based treatments for inherited blood disorders have been successful.
Research into engineering artificial organs that mimic the functions of human lymph nodes at The University of Alabama in Huntsville has garnered one of its professors a $507,777 National Science Foundation Faculty Early Career Development Program Award.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Lianne Margaret Dehnam, ANP BC 1235 Whitehorse Mercerville Rd, Suite 316 Bldg. C, Mercerville, NJ 08619-3810 Ph: (609) 581-5586 | Ms Lianne Margaret Dehnam, ANP BC 1235 Whitehorse Mercerville Rd, Suite 316 Bldg. C, Mercerville, NJ 08619-3810 Ph: (609) 581-5586 |
News Archive
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today released an examination of the federal government's system to produce medications, vaccines, equipment and supplies needed for a health emergency, known as medical countermeasures. The Public Health Emergency Medical Countermeasure Enterprise Review: Transforming the Enterprise to Meet Long Range National Needs reviews the process and makes recommendations for a better approach.
We constantly grow new skin and slough off the old. Until now, scientists have never agreed on exactly how this works, but new research from the University of Sheffield may provide the answer.
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
The first two clinical trials for CRISPR-based treatments for inherited blood disorders have been successful.
Research into engineering artificial organs that mimic the functions of human lymph nodes at The University of Alabama in Huntsville has garnered one of its professors a $507,777 National Science Foundation Faculty Early Career Development Program Award.
› Verified 1 days ago